Pharma BD Deal Intelligence
CStone Pharmaceuticals and Pfizer announced a strategic collaboration that includes Pfizer obtaining Greater China commercialization rights for sugemalimab and…
Pfizer has agreed to take Greater China licensing and commercialization rights to CStone Pharmaceuticals' PD-L1 cancer drug sugemalimab, the companies said on…
CStone Pharmaceuticals' sugemalimab won its first NMPA approval, in unresectable Stage III NSCLC after chemoradiation, the same setting where AstraZeneca's…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Pfizer licensed China commercialization rights to CStone's sugemalimab (PD-L1 antibody), paying $200M upfront including an $80M equity investment.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / CStone Pharmaceuticals (this deal) | 2020 | $780M | 51 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2020 deals · Pfizer Inc. deals · Oncology deals